HPV infection associated DNA damage correlated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Kim K, Zang R, Choi SC, et al. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20(2):72–76. doi:10.3802/jgo.2009.20.2.7219590717
   PubMed Web of Science ®Google Scholar
• Adam ML, Pini C, Túlio S, et al. Assessment of the association between micronuclei and the degree of uterine lesions and viral load in women with human papillomavirus. Cancer Genomics Proteomics. 2015;12(2):67–71.25770189
   PubMed Web of Science ®Google Scholar
• Visalli G, Riso R, Facciolà A, et al. Higher levels of oxidative DNA damage in cervical cells are correlated with the grade of dysplasia and HPV infection. J Med Virol. 2016;88(2):336–344.26174792
   PubMed Web of Science ®Google Scholar
• Yu JS, Leng PF, Li YF, et al. Aryl hydrocarbon receptor suppresses the prostate cancer LNCaP cell growth and invasion by promoting DNA damage response under oxidative stress. DNA Cell Biol. 2017;36(11):1010–1017. doi:10.1089/dna.2017.378328972393
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi:10.1002/(ISSN)1096-989610451482
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M, Rittmüller C, Zur Hausen H, et al. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6–E7 anti-sense RNA. Int J Cancer. 1992;51(5):831–834.1319412
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Münger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–937. doi:10.1126/science.25631732537532
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–560. doi:10.1038/nrc288620592731
   PubMed Web of Science ®Google Scholar
• Hufbauer M, Cooke J, van der Horst GTJ, et al. Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis. Mol Cancer. 2015;14:183. doi:10.1186/s12943-014-0278-926511842
   PubMed Web of Science ®Google Scholar
• Yang L, Huangpu XM, Zhang SW, et al. Changes of mortality rate for cervical cancer during 1970’s and 1990’s periods in china. Acta Academiae Medicinae Sinicae. 2003;25(4):386–390.12974079
   PubMedGoogle Scholar
• Zhao J, Guo Z, Wang Q, et al. Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. Infect Agent Cancer. 2017;12:8. doi:10.1186/s13027-017-0116-y28138337
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Ellenson LH, Ronnett BM. Blaustein’s Pathology of the Female Genital Tract. 5th ed. New York: Springer; 2002.
   Google Scholar
• Shen Y, Gong J, He Y, et al. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. J Virol Methods. 2013;187(2):288–293. doi:10.1016/j.jviromet.2012.11.02423201290
   PubMed Web of Science ®Google Scholar
• Liu TY, Xie R, Luo L, et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. J Virol Methods. 2014;196:120–125. doi:10.1016/j.jviromet.2013.10.03224216236
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–870. doi:10.1038/nature0348215829956
   PubMed Web of Science ®Google Scholar
• Fan C, Quan R, Feng X, et al. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta. 2006;1763(10):1090–1097. doi:10.1016/j.bbamcr.2006.08.02616997395
   PubMed Web of Science ®Google Scholar
• Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106(3):396–403. doi:10.1002/ijc.1122212845680
   PubMed Web of Science ®Google Scholar
• Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307–315. doi:10.1038/nature0309815549092
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649. doi:10.1038/252929872311
   PubMed Web of Science ®Google Scholar
• Guo Z, Pei S, Si T, et al. Expression of the γ-phosphorylated histone H2AX in gastric carcinoma and gastric precancerous lesions. Oncol Lett. 2015;9(4):1790–1794. doi:10.3892/ol.2015.289625789044
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang Q, Li J, et al. Comparative study of phosphorylated histone H2AX expressions in the cervical cancer patients of pre- and postneoadjuvant chemotherapy. Eur J Gynaecol Oncol. 2015;36(3):318–322.26189260
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434(7035):907–913. doi:10.1038/nature0348515829965
   PubMed Web of Science ®Google Scholar
• Hong SY. DNA damage response is hijacked by human papillomaviruses to complete their life cycle. J Zhejiang Univ Sci B. 2017;18(3):215–232. doi:10.1631/jzus.B160030628271657
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. doi:10.1016/S0140-6736(07)61416-017826171
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–632. doi:10.1002/ijc.2286117405118
   PubMed Web of Science ®Google Scholar
• Lytwyn A, Sellors JW, Mahony JB, et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med. 2003;127(9):1169–1175. doi:10.1043/1543-2165(2003)127<1169:AHPTIT>2.0.CO;212946228
   PubMed Web of Science ®Google Scholar
• Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19(2):457–465.18202795
   PubMed Web of Science ®Google Scholar
• Molden T, Kraus I, Karlsen F, et al. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol. 2006;100(1):95–100. doi:10.1016/j.ygyno.2005.07.10816153696
   PubMed Web of Science ®Google Scholar
• Avanzi S, Alvisi G, Ripalti A. How virus persistence can initiate the tumorigenesis process. World J Virol. 2013;2(2):102–109. doi:10.5501/wjv.v2.i2.10224175234
   PubMedGoogle Scholar
• Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527. doi:10.1056/NEJMoa02164112571259
   PubMed Web of Science ®Google Scholar
• Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002;62(23):7075–7082.12460929
   PubMed Web of Science ®Google Scholar
• Spardy N, Covella K, Cha E, et al. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 2009;69(17):7022–7029. doi:10.1158/0008-5472.CAN-09-092519706760
   PubMed Web of Science ®Google Scholar
• Bester AC, Roniger M, Oren YS, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145(3):435–446. doi:10.1016/j.cell.2011.03.04421529715
   PubMed Web of Science ®Google Scholar
• Anacker DC, Moody CA. Modulation of the DNA damage response during the life cycle of human papillomaviruses. Virus Res. 2017;231:41–49. doi:10.1016/j.virusres.2016.11.00627836727
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoSPathog. 2009;5(10):e1000605.
   Web of Science ®Google Scholar
• Hollingworth R, Grand RJ. Modulation of DNA damage and repair pathways by human tumour viruses. Viruses. 2015;7(6):2542–2591. doi:10.3390/v705254226008701
   PubMed Web of Science ®Google Scholar
• Williams JS, Kunkel TA. Ribonucleotides in DNA: origins, repair and consequences. DNA Repair (Amst). 2014;19:27–37. doi:10.1016/j.dnarep.2014.03.02924794402
   PubMed Web of Science ®Google Scholar